Marco Puzzoni

1.5k citations

50 papers · 737 indexed · h-index 16

Impact in

Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in ⓘ

Oncology 36
- Colorectal Cancer Treatments and Studies 18
- Pancreatic and Hepatic Oncology Research 12
- Cancer Immunotherapy and Biomarkers 6
Pulmonary and Respiratory Medicine 17
- Gastric Cancer Management and Outcomes 9
- Lung Cancer Treatments and Mutations 5

Co-authors: Mario Scartozzi (49 shared papers)Laura Demurtas (15 shared papers)Pina Ziranu (28 shared papers)Eleonora Lai (23 shared papers)Andrea Pretta (23 shared papers)Stefano Mariani (15 shared papers)Valeria Pusceddu (27 shared papers)Clelia Donisi (17 shared papers)
Journals: Journal of Clinical Oncology (7 papers)Annals of Oncology (5 papers)British Journal of Cancer (3 papers)International Journal of Molecular Sciences (3 papers)Cancers (3 papers)
Partner nations: Italy United States Belgium

In The Last Decade

Marco Puzzoni

44 papers receiving 729 citations

Peers

Countries citing papers authored by Marco Puzzoni

Since Specialization

Citations

This map shows the geographic impact of Marco Puzzoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Puzzoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Puzzoni more than expected).

Fields of papers citing papers by Marco Puzzoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Puzzoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Puzzoni. The network helps show where Marco Puzzoni may publish in the future.

Co-authors

The 25 scholars most cited alongside Marco Puzzoni, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Marco Puzzoni Line = papers co-authored together Marco Puzzoni links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Immune Checkpoint Inhibitors in the Treatment of HCC Frontiers in Oncology ·Clelia Donisi, Marco Puzzoni, Pina Ziranu, Eleonora Lai, Stefano Mariani, Giorgio Saba, Valentino Impera, Marco Dubois, Mara Persano, Marco Migliari, Andrea Pretta, Nicole Liscia, Giorgio Astara, Mario Scartozzi	2021	92
2	Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy Journal of Cardiovascular Medicine ·Clelia Madeddu, Martino Deidda, Alessandra Piras, Christian Cadeddu Dessalvi, Laura Demurtas, Marco Puzzoni, Giovanna Piscopo, Mario Scartozzi, Giuseppe Mercuro	2016	91
3	New therapeutic targets in pancreatic cancer Cancer Treatment Reviews ·Eleonora Lai, Marco Puzzoni, Pina Ziranu, Andrea Pretta, Valentino Impera, Stefano Mariani, Nicole Liscia, P Soro, Francesca Musio, Mara Persano, Clelia Donisi, S. Tolu, Francesca Balconi, Annagrazia Pireddu, Laura Demurtas, Valeria Pusceddu, Silvia Camera, Francesco Sclafani, Mario Scartozzi	2019	76
4	Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy Critical Reviews in Oncology/Hematology ·Cinzia Solinas, Michele Porcu, Zuzana Hlavata, Pushpamali De Silva, Marco Puzzoni, Karen Willard‐Gallo, Mario Scartozzi, Luca Saba	2017	52
5	BRCA-mutant pancreatic ductal adenocarcinoma British Journal of Cancer ·Eleonora Lai, Pina Ziranu, Dario Spanu, Marco Dubois, Andrea Pretta, S. Tolu, Silvia Camera, Nicole Liscia, Stefano Mariani, Mara Persano, Marco Migliari, Clelia Donisi, Laura Demurtas, Valeria Pusceddu, Marco Puzzoni, Mario Scartozzi	2021	37
6	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications Critical Reviews in Oncology/Hematology ·Cinzia Solinas, G. Pusole, Laura Demurtas, Marco Puzzoni, R. Mascia, Gilberto Morgan, Riccardo Giampieri, Mario Scartozzi	2016	36
7	Colorectal Cancer Early Detection in Stool Samples Tracing CpG Islands Methylation Alterations Affecting Gene Expression International Journal of Molecular Sciences ·Ana Florencia Vega-Benedetti, Eleonora Loi, Loredana Moi, Sandro Orrù, Pina Ziranu, Andrea Pretta, Eleonora Lai, Marco Puzzoni, Letizia Ciccone, Andrea Casadei‐Gardini, Francesco Cabras, F. Fortunato, Angelo Restivo, Luigi Zorcolo, Mario Scartozzi, Patrizia Zavattari	2020	25
8	<p>Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials</p> OncoTargets and Therapy ·Andrea Casadei‐Gardini, Marco Puzzoni, Francesca Montagnani, Giorgia Marisi, Emiliano Tamburini, Alessandro Cucchetti, Leonardo Solaini, Francesco Giuseppe Foschi, Fabio Conti, Giorgio Ercolani, Stefano Cascinu, Mario Scartozzi	2019	24
9	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Critical Reviews in Oncology/Hematology ·Giuseppe Aprile, Francesca Negri, Francesco Giuliani, Elisa De Carlo, Davide Melisi, Francesca Simionato, Nicola Silvestris, Oronzo Brunetti, Francesco Leone, Donatella Marino, Daniele Santini, Emanuela Dell’Aquila, Tea Zeppola, Marco Puzzoni, Mario Scartozzi	2017	23
10	Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? European Journal of Endocrinology ·Fabiana Pani, Matteo Massidda, Valeria Pusceddu, Marco Puzzoni, Elena Massa, Clelia Madeddu, Mario Scartozzi, Stefano Mariotti	2017	21
11	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial European Journal of Cancer ·Giuseppe Pasqualetti, Marta Schirripa, Emmanuelle Dochy, Matteo Fassan, Pina Ziranu, Marco Puzzoni, Mario Scartozzi, Giulia Alberti, Sara Lonardi, Vittorina Zagonel, Fabio Monzani, Fotios Loupakis	2020	20
12	Immunotherapy and Cancer: The Multi-Omics Perspective International Journal of Molecular Sciences ·Clelia Donisi, Andrea Pretta, Valeria Pusceddu, Pina Ziranu, Eleonora Lai, Marco Puzzoni, Stefano Mariani, Elena Massa, Clelia Madeddu, Mario Scartozzi	2024	20
13	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab British Journal of Cancer ·Laura Demurtas, Marco Puzzoni, Riccardo Giampieri, Pina Ziranu, Valeria Pusceddu, Alessandra Mandolesi, Chiara Cremolini, Gianluca Masi, Fabio Gelsomino, Carlotta Antoniotti, Cristian Loretelli, Fausto Meriggi, Alberto Zaniboni, Alfredo Falcone, Stefano Cascinu, Mario Scartozzi	2017	18
14	Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis Scientific Reports ·Riccardo Giampieri, Michela Del Prete, Tiziana Prochilo, Marco Puzzoni, Valeria Pusceddu, Fabiana Pani, Elena Maccaroni, R. Mascia, Maria Giuditta Baleani, Tania Meletani, Rossana Berardi, Anna Lanzillo, Stefano Mariotti, Alberto Zaniboni, Stefano Cascinu, Mario Scartozzi	2017	18
15	BRAF-mutant colorectal cancer, a different breed evolving Expert Review of Molecular Diagnostics ·Eleonora Lai, Andrea Pretta, Valentino Impera, Stefano Mariani, Riccardo Giampieri, Laura Casula, Valeria Pusceddu, Pierpaolo Coni, Daniela Fanni, Marco Puzzoni, Laura Demurtas, Pina Ziranu, Gavino Faa, Mario Scartozzi	2018	18
16	CD44: A New Prognostic Marker in Colorectal Cancer? Cancers ·Pina Ziranu, Andrea Pretta, Valentina Aimola, Flaviana Cau, Stefano Mariani, Alessandra Pia D’Agata, Claudia Codipietro, Daiana Rizzo, Veronica Dell’Utri, Giorgia Sanna, Giusy Moledda, Andrea Cadoni, Eleonora Lai, Marco Puzzoni, Valeria Pusceddu, Massimo Castagnola, Mario Scartozzi, Gavino Faa	2024	16
17	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? Targeted Oncology ·Marco Puzzoni, Nicola Silvestris, Francesco Leone, Riccardo Giampieri, Luca Faloppi, Laura Demurtas, Emanuela Dell’Aquila, Donatella Marino, Oronzo Brunetti, Silvio Ken Garattini, Elena Ongaro, Giorgio Astara, L. Orgiano, Giuseppe Aprile, Daniele Santini, Mario Scartozzi	2016	15
18	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study Targeted Oncology ·Luca Faloppi, Marco Puzzoni, Andrea Casadei‐Gardini, Nicola Silvestris, Gianluca Masi, Giorgia Marisi, Caterina Vivaldi, Cosmo Damiano Gadaleta, Pina Ziranu, Maristella Bianconi, Cristian Loretelli, Laura Demurtas, Eleonora Lai, Riccardo Giampieri, Gennaro Galizia, Paola Ulivi, Nicola Battelli, Alfredo Falcone, Stefano Cascinu, Mario Scartozzi	2020	14
19	Cholangiocarcinoma: new perspectives for new horizons Expert Review of Gastroenterology & Hepatology ·Margherita Rimini, Marco Puzzoni, Federica Pedica, Nicola Silvestris, Lorenzo Fornaro, Giuseppe Aprile, Eleonora Loi, Oronzo Brunetti, Caterina Vivaldi, Francesca Simionato, Patrizia Zavattari, Mario Scartozzi, Valentina Burgio, Francesca Ratti, Luca Aldrighetti, Stefano Cascinu, Andrea Casadei‐Gardini	2021	13
20	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study Clinical Colorectal Cancer ·Marta Schirripa, Giuseppe Pasqualetti, Riccardo Giampieri, Mario Scartozzi, Sara Lonardi, Laura Rumano', Francesca Bergamo, Silvia Stragliotto, Sabina Murgioni, Giulia Alberti, Mario Domenico Rizzato, Alessandra Anna Prete, Marco Puzzoni, Valeria Pusceddu, Pina Ziranu, Fabiana Pani, Stefano Mariotti, Vittorina Zagonel, Fabio Monzani, Fotios Loupakis	2018	11

About Marco Puzzoni

Marco Puzzoni is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Hepatology and Pathology and Forensic Medicine, having authored 50 papers that have together received 737 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (18 papers), Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Pancreatic and Hepatic Oncology Research (12 papers), Cancer Genomics and Diagnostics (10 papers), Gastric Cancer Management and Outcomes (9 papers), Genetic factors in colorectal cancer (8 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Lung Cancer Treatments and Mutations (5 papers). The work is most often cited by research in Oncology (438 citations), Hepatology (101 citations), Cancer Research (159 citations), Pathology and Forensic Medicine (110 citations) and Pulmonary and Respiratory Medicine (174 citations). Marco Puzzoni has collaborated with scholars based in Italy, United States and Belgium. Frequent co-authors include Mario Scartozzi, Laura Demurtas, Pina Ziranu, Eleonora Lai, Andrea Pretta, Stefano Mariani, Valeria Pusceddu, Clelia Donisi, Nicole Liscia and Mara Persano. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, International Journal of Molecular Sciences and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact